ライフサイエンスコーパス: inosine

1 , A = adenine, T= thymine, C = cytosine, I = inosine).

2 ystemic treatment with the purine nucleoside inosine.

3 from cells and catabolized by deamination to inosine.

4 ine deaminase (ADA) catabolizes adenosine to inosine.

5 0% of adenosine residues may be converted to inosine.

6 display increased circulating bile acids and inosine.

7 anslation are independent of the presence of inosine.

8 dergo RNA editing that converts adenosine to inosine.

9 ing by deamination of specific adenosines to inosine.

10 bacterium to growth arrest by adenosine and inosine.

11 m its ability to regulate both NF-kappaB and inosine.

12 single step from unactivated and unprotected inosine.

13 2B antagonist PSB603 prevented the effect of inosine.

14 s to restore levels of the purine metabolite inosine.

15 adenosine 34 of tRNA(Opt)AUG is converted to inosine.

16 ages at the second phosphodiester bond 3' to inosine.

17 Rs) deaminate adenosines in dsRNA to produce inosines.

18 cules are post-transcriptionally modified to inosines.

19 Inosine (1 mM) delivered intravesically to SCI rats duri

20 In isolated tissue assays, inosine (1 mM) significantly decreased the amplitude of

21 Treatment with inosine (100 mg/kg i.p. at 1, 24 and 48 h following CHI)

22 enzyme defect leading to the accumulation of inosine, 2'-deoxy-inosine (dIno), guanosine, and 2'-deox

23 ing a third universal bacterial primer pair (inosine-341f and 1492r).

24 e ribose (cADPR) analogs based on the cyclic inosine 5'-diphosphate ribose (cIDPR) template were synt

25 tal synthesis, analogues based on the cyclic inosine 5'-diphosphate ribose (cIDPR) template were synt

26 In Jurkat T cells, unlike the parent cyclic inosine 5'-diphosphoribose N1-cIDPR 2, 6-thio N1-cIDPR a

27 yclic product 6-thio N1-cIDPR (6-thio cyclic inosine 5'-diphosphoribose, 3), although the correspondi

28 g responses, specifically to l-glutamate and inosine 5'-monophosphate (IMP) mixtures in a heterologou

29 When inosine 5'-monophosphate (IMP), a ribonucleotide that po

30 po") form and in complex with its substrate, inosine 5'-monophosphate (IMP), and product, xanthosine

31 of a combination of monosodium glutamate and inosine 5'-monophosphate (MSG/IMP) provided either alone

32 preload with added monosodium glutamate and inosine 5'-monophosphate (MSG/IMP+) or without added mon

33 +) or without added monosodium glutamate and inosine 5'-monophosphate (MSG/IMP-) were consumed on 4 n

34 Inosine 5'-monophosphate acts synergistically with MSG w

35 s (monophosphates of inosinate or guanylate, inosine 5'-monophosphate and guanosine-5'-monophosphate)

36 Cryptosporidium inosine 5'-monophosphate dehydrogenase (CpIMPDH) has eme

37 Inosine 5'-monophosphate dehydrogenase (IMP dehydrogenas

38 nosine 5'-monophosphate reductase (GMPR) and inosine 5'-monophosphate dehydrogenase (IMPDH) are purin

39 Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyses

40 Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyzes

41 guanine or guanosine and therefore relies on inosine 5'-monophosphate dehydrogenase (IMPDH) for biosy

42 This parasite relies on inosine 5'-monophosphate dehydrogenase (IMPDH) to obtain

43 sine in a streamlined pathway that relies on inosine 5'-monophosphate dehydrogenase (IMPDH).

44 Since the introduction of the inosine 5'-monophosphate dehydrogenase inhibitors (mycop

45 gly, particularly in direct comparisons with inosine 5'-monophosphate dehydrogenase inhibitors.

46 target a key enzyme in this salvage process, inosine 5'-monophosphate dehydrogenase.

47 tides such as guanosine-5'-monophosphate and inosine 5'-monophosphate, which also elicit the umami ta

48 conversion of phosphoribosylpyrophosphate to inosine 5'-monophosphate.

49 Experiments with the substrate analogue inosine 5'-triphosphate further demonstrate that it is t

50 codynamic measurements require evaluation of inosine-5'-monophosphate dehydrogenase (IMPDH) activity,

51 revealed that the parasite relies solely on inosine-5'-monophosphate dehydrogenase (IMPDH) for the b

52 Inosine-5'-monophosphate dehydrogenase (IMPDH) is an ess

53 e] 1 alpha subcomplex subunit 9 (NDUFA9) and inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) as ace

54 , p38alpha signaling increases expression of inosine-5'-monophosphate dehydrogenase 2 in HSPCs, leadi

55 These results suggest that MPA inhibits inosine-5'-monophosphate dehydrogenase activity in eryth

56 -7 cells treated with MPA showed a decreased inosine-5'-monophosphate dehydrogenase activity.

57 2'-AMP (10-fold), adenosine (4.2-fold), and inosine (6.1-fold) while slightly increasing 5'-AMP (2.4

58 or paraspeckles, as well as for adenosine to inosine (A to I) RNA editing of Ctn RNA in muscle cells.

59 hough the overall prevalence of adenosine-to-inosine (A-to-I) editing and its specific functional imp

60 Altered levels of adenosine-to-inosine (A-to-I) editing are observed in several disease

61 regions of brain showed higher adenosine to inosine (A-to-I) editing in mature miRNAs.

62 Adenosine-to-inosine (A-to-I) editing is a highly prevalent posttrans

63 Adenosine-to-inosine (A-to-I) editing is a site-selective post-transc

64 Adenosine-to-inosine (A-to-I) editing of dsRNA by ADAR proteins is a

65 Adenosine-to-inosine (A-to-I) editing of RNA transcripts is an increa

66 ding RNAs (e.g. microRNAs), and adenosine-to-inosine (A-to-I) editing, generated by adenosine deamina

67 seed" sequence modifications by adenosine-to-inosine (A-to-I) editing.

68 pts that have been subjected to adenosine-to-inosine (A-to-I) editing.

69 Abnormal adenosine to inosine (A-to-I) messenger RNA (mRNA) editing has been l

70 Genome Atlas and identified 19 adenosine-to-inosine (A-to-I) RNA editing hotspots.

71 Adenosine to Inosine (A-to-I) RNA editing is a co- or post-transcript

72 Adenosine-to-inosine (A-to-I) RNA editing is a conserved post-transcr

73 Adenosine-to-inosine (A-to-I) RNA editing is a neurodevelopmentally r

74 Adenosine-to-Inosine (A-to-I) RNA editing is a post-transcriptional m

75 Adenosine-to-inosine (A-to-I) RNA editing is a widespread post-transc

76 Adenosine-to-inosine (A-to-I) RNA editing leads to transcriptome dive

77 es in neural activity can alter adenosine-to-inosine (A-to-I) RNA editing, a post-transcriptional sit

78 Adenosine-to-inosine (A-to-I) RNA editing, catalysed by ADAR enzymes

79 Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by Adenosine DeA

80 Adenosine-to-inosine (A-to-I) RNA editing, in which genomically encod

81 atalyze the editing of adenosine residues to inosine (A-to-I) within RNA sequences, mostly in the int

82 s the conversion of adenosine nucleosides to inosine (A-to-I), mediated by the ADAR family of enzymes

83 e type of RNA editing converts adenosines to inosines (A-->I editing) in double-stranded RNA (dsRNA)

84 newly available thermodynamic parameters for inosine, a modified adenine base with an universal base

85 Inosine, a naturally occurring purine nucleoside, has be

86 Following unilateral stroke in rats, inosine, a naturally occurring purine nucleoside, stimul

87 Inosine, a naturally occurring purine nucleoside, stimul

88 Biochemically, they convert adenosine to inosine, a nucleotide that is read as guanosine during t

89 NA) catalyzes the conversion of adenosine to inosine, a process known as A-to-I editing.

90 These results reveal that the microbiota-inosine-A2A receptor axis might represent a potential av

91 These findings demonstrate that inosine acts via an A2B receptor-mediated pathway that i

92 -AMP (26,000-fold), adenosine (53-fold), and inosine (adenosine metabolite, 30-fold).

93 in which adenosine residues are converted to inosine (adenosine-to-inosine editing).

94 Thus, inosine alters gene expression in neurons contralateral

95 AppN caps, we show that aprataxin hydrolyzes inosine and 6-O-methylguanosine caps, but is not adept a

96 on the mutant transporter at the expense of inosine and guanosine affinity due to weakened contacts

97 ously described trimeric PNP that can cleave inosine and guanosine only and a second, novel PNP (Ado-

98 While Ado was the preferred substrate, inosine and guanosine were also cleaved, with 43% and 32

99 Nucleosides and nucleotides (e.g., inosine and inosine monophosphate) were also found to be

100 lysis of B. anthracis spores germinated with inosine and L-alanine, we previously determined kinetic

101 Concentrations of inosine and leucine were significantly different between

102 which were also required for the efficacy of inosine and of L. reuteri in vivo.

103 se constituent nucleosides are adenosine and inosine and that vary by ribose substitution, internucle

104 preferentially targets the purine ribosides inosine and xanthosine, while the other is more active t

105 nd, novel PNP (Ado-PNP) that can cleave Ado, inosine, and guanosine.

106 series of imides, azinones (including AZT), inosines, and cyclic sulfonamides has been examined.

107 lites, including xanthine, hypoxanthine, and inosine are elevated.

108 The molecular changes induced by inosine are unknown, as is the ability of inosine to res

109 oward which the corresponding sugar-modified inosines are compared.

110 advancing to more definitive development of inosine as a potential disease-modifying therapy for PD.

111 sponsible for the conversion of adenosine to inosine at specific locations in cellular RNAs.

112 R2 catalyses the deamination of adenosine to inosine at the GluR2 Q/R site in the pre-mRNA encoding t

113 Inosine attenuates transcriptional changes caused by the

114 Inosine augments neurons' intrinsic growth potential by

115 RNA, specific adenosines can be converted to inosines, biological mimics for guanosine.

116 sage of the endospore germinants, alanine or inosine but not degradative enzymes or antibodies.

117 the recombinant protein and cleaves RNA with inosine but not DNA.

118 the deamination of particular adenosines to inosine by adenosine deaminases acting on RNA (ADARs).

119 an cells as HAPR is primarily metabolized to inosine by direct dehydroxylamination catalyzed by adeno

120 The growth inhibitory effect of inosine can be rescued by second-site suppressor mutatio

121 her nucleophiles also worked (e.g., MocVinyl-inosines can be cleaved with succinimide anion).

122 Because ADA converts adenosine to inosine, cells lacking this enzyme might be subject to p

123 teral stroke in the rat forelimb motor area, inosine combined with NEP1-40, a Nogo receptor antagonis

124 ated using 5'-labeled and internally-labeled inosine-containing DNA and a H214D mutant that is defect

125 ent for wild-type levels of germination with inosine-containing germinants in the absence of other re

126 RNAs may undergo hyper-editing, the role for inosine-containing hyper-edited double-stranded RNA in c

127 stimulates hEndoV activity and affinity for inosine-containing RNA.

128 lated in cells to avoid aberrant cleavage of inosine-containing transcripts.

129 build-up of its degradation products, mainly inosine (control: 13.25; urchins held in air: 82.87 and

130 Adenosine-to-inosine conversion (A-to-I editing), a posttranscription

131 rmant spores and subsequent germination with inosine, d-glucose, or l-valine, respectively, germinate

132 active Cas13 (dCas13) to direct adenosine-to-inosine deaminase activity by ADAR2 (adenosine deaminase

133 donuclease, Tma endonuclease V also exhibits inosine-dependent 3'-exonuclease activity.

134 In addition to its well-known inosine-dependent endonuclease, Tma endonuclease V also

135 Polymer-supported O(6)-(benzotriazol-1-yl)inosine derivatives (Pol-I and Pol-dI) have been synthes

136 range of the chemosensor was 0.5-50 muM with inosine detectability of 0.62 muM.

137 The imprinting factor for inosine, determined from piezomicrogravimetric experimen

138 o participant developed gout and 3 receiving inosine developed symptomatic urolithiasis.

139 Mean levels of guanosine, inosine, dGuo, and dIno were 4.4, 133.3, 3.6, and 3.8 mu

140 Inosine did not affect CST sprouting in the lumbar spina

141 ing to the accumulation of inosine, 2'-deoxy-inosine (dIno), guanosine, and 2'-deoxy-guanosine (dGuo)

142 Inosine, dIno, guanosine, and dGuo were tested by using

143 y deamination of specific adenosine bases to inosines during pre-mRNA processing generates edited iso

144 directly visualize and quantify adenosine-to-inosine-edited transcripts in situ.

145 clear retention correlates with adenosine-to-inosine editing and is in paraspeckle-associated complex

146 ty to the tandem dsRBDs from an adenosine-to-inosine editing enzyme, ADAR2 in complex with a substrat

147 spatio-temporal requirements of adenosine to inosine editing for correct behavior are unclear.

148 A adenosine deaminases catalyze adenosine-to-inosine editing in position 34 of several cytosolic tRNA

149 We also describe how adenosine-to-inosine editing influences SINE function and how ongoing

150 Adenosine-to-inosine editing is one of the most frequent post-transcr

151 RATIONALE: Adenosine-to-inosine editing of microRNAs has the potential to cause

152 on, we identified and validated adenosine-to-inosine editing of the miR487b seed sequence.

153 angiomiR miR487b is subject to adenosine-to-inosine editing or 2'-O-ribose-methylation during neovas

154 Adenosine to inosine editing within untranslated regions of eri-6 and

155 idues are converted to inosine (adenosine-to-inosine editing).

156 ever, has been shown to inhibit adenosine-to-inosine editing.

157 d, placebo-controlled, dose-ranging trial of inosine, enrolled participants from 2009 to 2011 and fol

158 NA-editing enzyme that converts adenosine to inosine, following RNA transcription.

159 le-helical DNA molecules substituting either inosine for guanosine or 2,6-diaminopurine for adenine.

160 ty, methoxyamine capping of the Ap aldehyde, inosine-for-guanine replacement, hydroxyl radical footpr

161 '-14C], [9-15N], [1'-14C, 9-15N] and [5'-3H2]inosines gave intrinsic KIE values of 1.210, 1.075, 1.03

162 quential replacement of canonical bases with inosine greatly simplifies the problem and defines a new

163 rum urate rose by 2.3 and 3.0 mg/dL in the 2 inosine groups (P < .001 for each) vs placebo, and cereb

164 spinal fluid urate level was greater in both inosine groups (P = .006 and <.001, respectively).

165 , occurred at the same or lower rates in the inosine groups relative to placebo.

166 he flanking purine, decreasing in the order: inosine > adenine > guanine > deazaguanine.

167 city, a genetic selection for mutants of the inosine-guanosine-specific Crithidia fasciculata nucleos

168 Editing of adenosine (A) to inosine (I) at the first anticodon position in tRNA is c

169 ct on RNA (ADARs) carry out adenosine (A) to inosine (I) editing reactions with a known requirement f

170 the deamination of adenosine (A) to produce inosine (I) in double-stranded (ds) RNA structures, a pr

171 C-6 deamination of adenosine (A) to produce inosine (I) in RNA substrates with a double-stranded cha

172 e Acting on RNA (ADAR2) that deaminates A to inosine (I) residues that are subsequently translated as

173 pression both by catalyzing adenosine (A) to inosine (I) RNA editing and binding to regulatory elemen

174 C-6 deamination of adenosine (A) to produce inosine (I), which behaves as guanine (G), thereby alter

175 me ADAR chemically modifies adenosine (A) to inosine (I), which is interpreted by the ribosome as a g

176 A(Arg1,2) are also modified at positions 34 (inosine, I(34)) and 37 (2-methyladenosine, m(2)A(37)).

177 Inosine (IC50 = 3.7 microM) and guanosine (IC50 = 21.3 m

178 (ADARs) catalyze deamination of adenosine to inosine in a double-stranded structure found in various

179 ctability compares well to the levels of the inosine in body fluids which are in the range 0-2.9 micr

180 e the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) and thereby poten

181 NA editing enzymes that convert adenosine to inosine in double-stranded RNA (dsRNA).

182 Rs) catalyze the deamination of adenosine to inosine in double-stranded RNA templates, a process know

183 R1 catalyzes the deamination of adenosine to inosine in double-stranded RNA.

184 genomically encoded adenosine is changed to inosine in RNA, is catalyzed by adenosine deaminase acti

185 th and inefficient editing from adenosine to inosine in six nucleus-encoded tRNA species.

186 miR-4459 and hsa-miR-135a-3p expression with inosine in the vein tissue, while miR-216a-5p, conversel

187 V (EndoV) is an enzyme with specificity for inosines in nucleic acids.

188 RNA editing converts single adenosines into inosines in pre-mRNA.

189 n RNAs (ADARs) convert adenosine residues to inosines in primary microRNA (pri-miRNA) transcripts to

190 As inosines in RNA are highly abundant, hEndoV activity is

191 f the conversion of specific adenosines into inosines in RNA molecules.

192 A urinary metabolite panel, comprising inosine, indole-3-acetate, galactose, and an N-acetylate

193 hosphate (AMP), inosine monophosphate (IMP), inosine (Ino) and hypoxanthine (Hx), in fish tissue, bas

194 toring molecules such as adenosine (Ado) and inosine (Ino) in the central nervous system has enabled

195 We also measured ADO and inosine (INO) levels in tissues by mass spectrometry.

196 lation of ATP into Ado, Ado deamination into inosine (Ino), and nucleoside uptake.

197 Conversion of adenosine to inosine is a frequent type of RNA editing, but important

198 Inosine is now in clinical trials for other indications,

199 Since inosine is recognized during translation as guanosine, t

200 Feeding inosine itself prolonged life and inhibited multiorgan i

201 e metabolism, most notably by an increase in inosine levels.

202 monophosphate) and nucleoside (adenosine and inosine) levels were quantified by high-performance liqu

203 es, bulge loops, CNG repeats, dangling ends, inosines, locked nucleic acids, 2-hydroxyadenines and az

204 equilibrating Michaelis complexes (PNP.PO(4).inosine <--> PNP.Hx.R-1-P) and inhibited complexes (PNP.

205 hat CT significantly decreased the levels of inosine, lysine, putrescine, and xanthine at the gingivi

206 Our results suggest that inosine may improve functional outcome after TBI.

207 ctic measure during nitroprusside treatment, inosine may serve as a biomarker of cyanide exposure, an

208 mmune sensing, and functions of adenosine to inosine modifications in retroviral life cycles.

209 Inosine monophosphate (IMP) dehydrogenase 2 (IMPDH2) is

210 al enzyme that catalyzes steps 2, 3 and 5 of inosine monophosphate (IMP) synthesis.

211 sphate (ADP), adenosine monophosphate (AMP), inosine monophosphate (IMP), inosine (Ino) and hypoxanth

212 le in the formation of the key intermediates inosine monophosphate and AMP involved in the synthesis

213 carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC) and thereby

214 -4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase, Steps 9 and 10), w

215 Interindividual variation in inosine monophosphate dehydrogenase (IMPDH) enzyme activ

216 The guanine nucleotide biosynthetic enzyme inosine monophosphate dehydrogenase (IMPDH) forms octame

217 MPA is a potent inosine monophosphate dehydrogenase (IMPDH) inhibitor bu

218 The inosine monophosphate dehydrogenase (IMPDH) protein GuaB

219 We recently reported that Inosine Monophosphate Dehydrogenase (IMPDH), a rate-limi

220 MPA selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a rate-limi

221 tem and hypoxanthine require the activity of inosine monophosphate dehydrogenase (IMPDH), the rate-li

222 Antibodies to inosine monophosphate dehydrogenase 2 (IMPDH2) and cytid

223 erimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has s

224 ere-associated protein E (Cenpe), Gpr49, and inosine monophosphate dehydrogenase type II] with previo

225 al steps from phosphoribosylpyrophosphate to inosine monophosphate were recently shown to associate i

226 cleosides and nucleotides (e.g., inosine and inosine monophosphate) were also found to be transformed

227 nce of several umami (uridine monophosphate, inosine monophosphate, adenosine, and guanosine) and kok

228 inamide adenine dinucleotide (NAD)-mimicking inosine monophsophate dehydrogenase (IMPDH) inhibitors h

229 ntral intermediate in purine catabolism, the inosine nucleobase hypoxanthine is also one of the most

230 tic versatility of the O6-(benzotriazol-1-yl)inosine nucleoside derivatives for the assembly of relat

231 nsfer reaction between O6-(benzotriazol-1-yl)inosine nucleosides and bis(pinacolato)diboron (pinB-Bpi

232 t of BtO(-) from the O(6)-(benzotriazol-1-yl)inosine nucleosides by azide anion.

233 resent study, we investigated the effects of inosine on motor and cognitive deficits, CST sprouting,

234 A) catalyzes the deamination of adenosine to inosine on RNA substrates with double-stranded character

235 Mechanistically, the inhibition of inosine on the differentiation of Th1 and Th2 cells in v

236 undamaged cortex well beyond those seen with inosine or EE alone.

237 red by the related purine metabolite 5'-AMP, inosine, or hypoxanthine.

238 dissection and microarray analysis show that inosine profoundly affects gene expression in corticospi

239 al sensor for selective determination of the inosine, renal disfunction biomarker, was devised and pr

240 RNA editing that converts adenosine to inosine replaces the gene-encoded Ile, Asn, and Ile (INI

241 idine or adenosine nucleotides to uridine or inosine, respectively, in mRNAs.

242 Adenosine to inosine RNA editing catalyzed by ADAR enzymes is common

243 Informational recoding by adenosine-to-inosine RNA editing diversifies neuronal proteomes by ch

244 and a propensity for increased adenosine-to-inosine RNA editing during CML progression.

245 Since adenosine-to-inosine RNA editing has recently emerged as a driver of

246 Adenosine-to-inosine RNA editing in transcripts encoding the voltage-

247 While adenosine-to-inosine RNA editing is consistently deregulated in cance

248 Post-transcriptional adenosine-to-inosine RNA editing mediated by adenosine deaminase acti

249 0% of human transcripts undergo adenosine to inosine RNA editing, and editing is required for normal

250 acting on RNA (ADAR)-dependent adenosine-to-inosine RNA editing.

251 ; (3) enhances the frequency of adenosine-to-inosine RNA editing; and (4) dramatically increases the

252 ochemically interacted with the adenosine-to-inosine RNA-editing enzyme dADAR.

253 ingly deprotonated forms of hypoxanthine and inosine show drastic differences, where the latter remai

254 3'-AMP increased secretion of adenosine and inosine similar to that achieved by 5'-AMP.

255 The dependence on an inosine site and the exonuclease nature of the 3'-exonuc

256 editing that converts adenosine residues to inosine specifically in double-stranded RNAs.

257 olecular inversion probes were designed with inosine strategically positioned to complement suspected

258 A guanine-to-inosine substitution, which selectively knocks out a Wat

259 ic acid substituents, in the presence of the inosine template and a thiophene cross-linker.

260 For that purpose, inosine-templated molecularly imprinted polymer (MIP) fi

261 of AICAR were mimicked by adenosine but not inosine, the metabolites of AICAR.

262 domized to 1 of 3 treatment arms: placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or mode

263 the genes responsible for the conversion of inosine to AMP (gsk, purA, and purB) as well as by the p

264 by inosine are unknown, as is the ability of inosine to restore complex functions associated with a s

265 pyrimidine-2,4-diones (AZT derivatives), or inosines to the electron-deficient triple bonds of methy

266 embrane domain 4 was found to interfere with inosine transport capability, indicating that this helix

267 condary analyses demonstrated nonfutility of inosine treatment for slowing disability.

268 Genetic variation of inosine triphosphatase (ITPA) causing an accumulation of

269 Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triph

270 Inosine triphosphatase (ITPA) variants causing ITPase de

271 e inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect again

272 C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to

273 ere we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thoug

274 t enzymes involved in the purine metabolism (inosine triphosphatase, 5'-nucleotidase cytosolic-II, pu

275 hosphatase (ITPA) causing an accumulation of inosine triphosphate (ITP) has been shown to protect pat

276 single-nucleotide polymorphism (SNP) in the inosine triphosphate (ITPA) gene and hemolytic anemia in

277 Pauses triggered by inosine triphosphate misincorporation led to backtrackin

278 hosphate] into nucleic acids is prevented by inosine triphosphate pyrophosphatase (ITPA).

279 dy evaluated the impact of variations in the inosine triphosphate pyrophosphatase (ITPase) gene (ITPA

280 loss of function mutations in ITPA, encoding inosine triphosphate pyrophosphatase (ITPase).

281 ted to the sensorimotor cortex, we show that inosine triples the number of corticospinal tract axons

282 For example, an A-U, inosine*U and pseudouridine*A pair each form two hydroge

283 as to investigate the mechanism of action of inosine underlying improvement of NDO.

284 milar functional improvements were seen when inosine was combined with environmental enrichment (EE).

285 Inosine was generally safe, tolerable, and effective in

286 The effect of inosine was mimicked by the adenosine receptor agonist N

287 The inhibition of SA by inosine was not observed in the presence of the BK antag

288 utamate, taurine, myo-inositol, creatine and inosine were present in aqueous extracts and phosphatidy

289 xcitation of hypoxanthine and its nucleoside inosine were studied by femtosecond fluorescence up-conv

290 3H], [1'-14C], [2'-3H], [5'-3H], and [9-15N] inosines were 1.221, 1.035, 1.073, 1.062 and 1.025, resp

291 t deprotonation sites in hypoxanthine versus inosine, which gives rise to significantly different res

292 editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.

293 the C-6 deamination of adenosine to produce inosine, which is recognized as guanosine, a process kno

294 The deamination of adenine yields inosine, which is treated as guanine by polymerases, but

295 can be alleviated by replacing guanine with inosine, which removes the N2 amino group that protrudes

296 Higher selectivity for inosine with respect to common interferents was also ach

297 The present study investigated whether inosine would complement the effects of treatments that

298 es--adenosine, cytidine, guanosine, uridine, inosine, xanthosine, pseudouridine, N(2)-methylguanosine

299 lB family transcriptional antiterminator, an inosine/xanthosine triphosphatase, GidA, a methyl-accept

300 Replacing guanosine with more weakly pairing inosine yielded an RNA that folded rapidly without a fac